Preview

Obstetrics, Gynecology and Reproduction

Advanced search

Combined hormonal contraceptives as a risk factor for cerebrovascular accident

https://doi.org/10.17749/2313-7347.2020.14.1.69-79

Full Text:

Abstract

Hormonal contraceptives are effective in preventing an unwanted pregnancy, but have side effects; among them stroke occupies an important place. The development of this serious disease may be associated with the hormonal drug components, but heavily dependent on additional risk factors for vascular and thrombotic complications such as smoking, arterial hypertension, genetically determined and acquired predisposition to thrombotic complications. This review presents an analysis of the most important risk factors for stroke such as genetic predisposition, hyperhomocysteinemia, thrombophilias in women using combined oral contraceptives.

About the Authors

M. G. Novosartyan
Kuban State Medical University, Health Ministry of Russian Federation
Russian Federation

Margarita G. Novosartyan - MD, Obstetrician-Gynecologist, Postgraduate Student, Department of Obstetrics, Gynecology and Perinatology.

4 Mitrofana Sedina St, Krasnodar 350063



N. V. Samburova
Sechenov University
Russian Federation

Natalia V. Samburova - MD, PhD, Associate Professor, Department of Pathophysiology, Institute of Clinical Medicine.

8 bild. 2, Trubetskaya St., Moscow 119991



E. V. Anichkova
Sechenov University
Russian Federation

Elizaveta V. Anichkova - 4th year student, Medical school Medicine of the Future.

8 bild. 2, Trubetskaya St., Moscow 119991



E. A. Bayanduryan
Kuban State Medical University, Health Ministry of Russian Federation
Russian Federation

Emmanuella A. Bayanduryan - MD, Obstetrician-Gynecologist, Postgraduate Student, Department of Obstetrics, Gynecology and Perinatology.

4 Mitrofana Sedina St, Krasnodar 350063



M. D. Andreeva
Kuban State Medical University, Health Ministry of Russian Federation
Russian Federation

Margarita D. Andreeva - MD, Dr Sci Med, Professor, Department of Obstetrics, Gynecology and Perinatology.

4 Mitrofana Sedina St, Krasnodar 350063



V. O. Bitsadze
Sechenov University
Russian Federation

Victoria O. Bitsadze - MD, Dr Sci Med, Professor, Department of Obstetrics and Gynecology, Institute of Children’s Health, Scopus Author ID: 6506003478, Researcher ID: F-8409-2017.

8 bild. 2, Trubetskaya St., Moscow 119991


References

1. Roach R.E., Helmerhorst F.M., Lijfering W.M. et al. Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev. 2015;27(8):CD011054. DOI: 10.1002/14651858.CD011054.pub2.

2. Xu Z., Yue Y., Bai J. et al. Association between oral contraceptives and risk of hemorrhagic stroke: a meta-analysis of observational studies. Arch Gynecol Obstet. 2018;297(5):1181-91. DOI: 10.1007/s00404-018-4723-7.

3. Khamoshina M.B., Mezhevitinova E.A., Rudneva O.D. et al. Hormonal contraception in women with a high risk for development of complications: facets of the problem and its solutions. [Gormonal’naya kontracepciya u zhenshchin s vysokim riskom razvitiya oslozhnenij: grani problemy, puti resheniya]. Voprosy ginekologii, akusherstva i perinatologii. 2012;11(3):41-7. (In Russ.).

4. Lima A.C.S, Martins L.C.G, Lopes M.V.O et al. Influence of hormonal contraceptives and the occurrence of stroke: integrative review. Rev Bras Enferm [Internet]. 2017;70(3):647-55. DOI: 10.1590/0034-7167-2016-0056.

5. Dulicek P., Ivanova E., Kostal M. et al. Analysis of risk factors of stroke and venous thromboembolism in females with oral contraceptives use. Clin Appl Thromb Hemost. 2018;24(5):797—802. DOI: 10.1177/1076029617727857.

6. Li F., Zhu L., Zhang J. et al. Oral contraceptive use and increased risk of stroke: A dose-response meta-analysis of observational studies. Front Neurol. 2019;(10):993. DOI: 10.3389/fneur.2019.00993.

7. Kuznetsova I.V., Sukhanova G.A. Contraception and the risk of arterial thrombosis. [Kontracepciya i risk arterial’nogo tromboza]. RMZh. Mat i Ditya. 2013;21(23):1128-33. (In Russ.).

8. Sibai B.M., Coppage K.H. Diagnosis and management of women with stroke during pregnancy/postpartum. Clin Perinatol. 2004;31(4):853-68. DOI: 10.1016/j.clp.2004.06.003.

9. Carlton C., Banks M., Sundararajan S. Oral contraceptives and ischemic stroke risk. Stroke. 2018;49(4):e157-e159. DOI: 10.1161/STROKEAHA.117.020084.

10. Champaloux S.W., Tepper N.K., Monsour M. et al. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol. 2017;16(5):489.e1—489.e7. DOI: 10.1016/j.ajog.2016.12.019.

11. Xu Zh., Li Y., Tang Sh. et al. Current use of oral contraceptives and the risk of first-ever ischemic stroke: A meta-analysis of observational studies. Thromb Res. 2015;1(136):52-60. DOI: 10.1016/j.thromres.2015.04.021.

12. Muminova M.S. Thromboembolic complications in the use of combined oral contraceptives. [Tromboembolicheskie oslozhneniya pri primenenii kombinirovannyh oral’nyh kontraceptivov]. Alleya nauki. 2018;8(11):96—100. (In Russ.).

13. Mozes V.G. Hormonal contraception in women from a risk group for development of arterial and venous thromboses. [Gormonal’naya kontracepciya u zhenshchin gruppy riska po razvitiyu arterial’nyh i venoznyh trombozov]. Voprosy ginekologii, akusherstva i perinatologii. 2009;8(2):83-7. (In Russ.).

14. Mezhevitinova E.A., Khamoshina M.B., Rudneva O.D. et al. Hormonal contraception in high-risk women: ways to solve the problem. [Gormonal’naya kontracepciya u zhenshchin vysokogo riska: puti resheniya problem]. Doktor.Pu. 2012;1(69):27-33. (In Russ.).

15. Girot M. Smoking and stroke. Presse Med. 2009;38(7—8):1120—5. (In French). DOI: 10.1016/j.lpm.2008.12.018.

16. Taitubayeva G.K., Gribacheva I.A., Petrova E.V., Popova T.F. Stroke and pregnancy: the main risk factors. [Popova T.F. Insul’t i beremennost’: osnovnye faktory riska]. Issledovaniya ipraktika vmedicine. 2017;4(4):27—34. (In Russ.). DOI: 10.17709/2409-2231-2017-4-4-3.

17. Kaminski P., Szpotanska-Sikorska M., Wielgos M. Cardiovascular risk and the use of oral contraceptives. Neuro Endocrinol Lett. 2013;34(7):587-9.

18. Medical admissibility criteria for using contraceptive methods. 5th ed. [Medicinskie kriterii priemlemosti dlya ispol’zovaniya metodov kontracepcii. 5-e izd]. Zheneva: VOZ, 2015. 192 s. (In Russ.). Available at: http://www.euro.who.int/ data/assets/pdf_file/0005/348116/MEC-merged.pdf. (Accessed: 05.12.2019).

19. Traylor M., Farrall M., Holliday E.G. et al; International Stroke Genetics Consortium. Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): a meta-analysis of genome-wide association studies. Lancet Neurol. 2012;11(11):951-62. DOI: 10.1016/S1474-4422(12)70234-X.

20. Wang Y., Tikellis C., Thomas M.C., Golledge J. Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis. 2013;226(1):3-8. DOI: 10.1016/j.atherosclerosis.2012.08.018.

21. Tsze D.S., Valente J.H. Pediatric stroke: a review. Emerg Med Int. 2011;2011:734506. DOI: 10.1155/2011/734506.

22. Bayanduryan E.A., Samburova N.V., Anichkova E.V. et al. Etiopathoge-netic risk factors for stroke in pregnant women. [Etiopatogeneticheskie faktory riska razvitiya insul’ta u beremennyh]. Akusherstvo, gine-kologiya ireprodukciya. 2019;13(3):217-26. (In Russ.). DOI: 10.17749/2313-7347.2019.13.3.217-226.

23. Pezzini A., Grassi M., Iacoviello L. et al. Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. J Neurol Neurosurg Psychiatry. 2007;78(3):271-6. DOI: 10.1136/jnnp.2006.101675.

24. Martinelli I., Battaglioli T., Burgo I. et al. Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006;91(6):844-7.

25. Aznar J., Mira Y., Vaya A. et al. Factor V Leiden and prothrombin G20210A mutations in young adults with cryptogenic ischemic stroke. Thromb Haemost. 2004;91(5):1031-4. DOI: 10.1160/TH03-11-0690.

26. Meinardi J.R., Middeldorp S., de Kam P.J. et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol. 2002;116(3):625-31. DOI: 10.1046/j.0007-1048.2001.03303.x

27. Casas J.P., Hingorani A.D., Bautista L.E., Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18 000 cases and 58 000 controls. Arch Neurol. 2004;61(11):652-61. DOI: 10.1001/archneur.61.11.1652.

28. Slooter A.J., Rosendaal F.R., Tanis B.C. et al. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost. 2005;3:1213-7. DOI: 10.1111/j.1538-7836.2005.01442.x.

29. Pizova N.V. Ischemic stroke and inherited thrombophilias. [Ishemicheskij insul’t i nasledstvennye trombofilicheskie sostoyaniya]. Annaly klinicheskoj i eksperimental’noj nevrologii. 2017;11(4):71-80. (In Russ.).

30. De Stefano V., Chiusolo P., Paciaroni K. et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood. 1998;91(10):3562-5.

31. Nowak-Gottl U., Strater R., Heinecke A., Junker R. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methy-lenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood. 1999;94(11):3678-82. DOI: 10.1182/blood.V94.11.3678.423k34_3678_3682.

32. Lalouschek W., Aull S., Series W. et al. The prothrombin G20210A mutation and factor V Leiden mutation in patients with cerebrovascular disease. Blood. 1998;92(2):704-5.

33. Wotherspoon F, Laight D, Shaw K, Cummings M. Homocysteine, endothelial dysfunction and oxidative stress in type 1 diabetes mellitus. Br J Diabetes Vasc Dis. 2003;3(5):334—40. DOI: 10.1177/14746514030030050401.

34. McCully K.S. Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation. Ann Clin Lab Sci. 2009;39(3):219—32.

35. Kozlova T.V. Significance of genetic disorders in hemocoagulation and hyperhomocystein system as a causing factor of cerebrovascular complications in patients with atrial fibrillation. [Znachimost’ geneticheskih narushenij v sisteme gemokoagulyacii i gipergomocisteinemii kak prichinnogo faktora cerebrovaskulyarnyh oslozhnenij u bol’nyh s fibrillyaciej predserdij]. Nevrologicheskij vestnik. 2005;37(1-2):26—31. (In Russ.)

36. Lonn E., Yusuf S., Arnold M.J. et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354(15):1567—7. DOI: 10.1056/NEJMoa060900.

37. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardiocerebrovascular risk. JAppl Genet. 2008;49(3):267-82. DOI: 10.1007/BF03195624.

38. Taylor F.B. Protein S, C4b binding protein, and the hypercoagulable state. J Lab Clin Med. 1992;119(6):596-7.

39. Wiesel M.L., Borg J.Y., Grunebaum L. et al. Influence of protein S deficiency on the arterial thrombosis risk. Presse Med. 1991;20(22):1023-7.

40. Douay X., Lucas C., Caron C. et al. Antithrombin, protein C and protein S levels in 127 consecutive young adults with ischemic stroke. Acta Neurol Scand. 1998;98(2):124-7.

41. Moster M. Coagulopathies and arterial stroke. J Neuroophthalmol. 2003;23(1):63-71. DOI: 10.1097/00041327-200303000-00012.

42. Smith F.B., Lee A.J., Fowkes F.G. et al. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17(11):3321-5. DOI: 10.1161/01.atv.17.11.3321.

43. Xu X., Li J., Sheng W., Liu L. Meta-analysis of genetic studies from journals published in China of ischemic stroke in the Han Chinese population. Cerebrovasc Dis. 2008;26:48-62. DOI: 10.1159/000135653.

44. Karpova I.A., Sigiljetova T.S., Chernova A.M. et al. The trombotic complications of women caused by hormonal contraception. [Tromboticheskie oslozhneniya na fone gormonal’noj kontracepcii u zhenshchin]. Medicinskaya nauka i obrazovanie Urala. 2012;13(3-2):12-5. (In Russ.)

45. Andersson H.M., Siegerink B., Luken B.M. et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555-60. DOI: 10.1182/blood-2011-09-380618.

46. Sukontseva T.A., Kaplina O.Yu. On the pathogenesis of thrombosis in antiphospholipid syndrome. [K voprosu o patogeneze trombozov pri antifosfolipidnom syndrome]. Akusherstvo, ginekologiya i reprodukciya. 2018;12(3):72-8. (In Russ.). DOI: 10.17749/2313-7347.2018.12.3.072-078.

47. Denorme F., Kraft P., Pareyn I. et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. PLoS One. 2017;12(6):e0179258. DOI: 10.1371/journal.pone.0179258.

48. Urbanus R.T. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol. 2009;11(8):998-1005. DOI: 10.1016/S1474-4422(09)70239-X.


For citation:


Novosartyan M.G., Samburova N.V., Anichkova E.V., Bayanduryan E.A., Andreeva M.D., Bitsadze V.O. Combined hormonal contraceptives as a risk factor for cerebrovascular accident. Obstetrics, Gynecology and Reproduction. 2020;14(1):69-79. (In Russ.) https://doi.org/10.17749/2313-7347.2020.14.1.69-79

Views: 227


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)